Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-756 pembrolizumab versus placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy in high-risk early-stage ER-positive/HER2-negative breast cancer
2023-506921-12-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pembrolizumab combination arm with Placebo combination arm (2 arms). Primary endpoints: Pathological complete response rate using the definition of ypT0/Tis ypN0 and Event-free survival. Planned start Dec 2018; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-506921-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506921-12-00.